COST-EFFECTIVENESS ANALYSIS OF NIRMATRELVIR/RITONAVIR COMPARED WITH MOLNUPIRAVIR IN PATIENTS AT HIGH RISK FOR PROGRESSION TO SEVERE COVID-19 IN JAPAN

被引：0
|
作者：
Yuasa, A. [1 ]
Matsuda, H. [2 ]
Fujii, Y. [3 ]
Kado, Y. [2 ]
Murata, K. [1 ]
Yoshida, M. [3 ]
Mugwagwa, T. [4 ]
Gu, Y. [5 ]
机构：
[1] Pfizer Japan Inc, Shibuya Ku, Tokyo, Japan
[2] IQVIA Solut Japan GK, Minato Ku, Tokyo, Japan
[3] Pfizer R&D Japan GK, Shibuya Ku, Tokyo, Japan
[4] Pfizer Inc, New York, NY USA
[5] Tokyo Med & Dent Univ, Bunkyo Ku, Tokyo, Japan
来源：
VALUE IN HEALTH | 2024年 / 27卷 / 12期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
EE180
引用
收藏
页码：S89 / S89
页数：1
相关论文
共 50 条
  • [1] Cost-Effectiveness of Oral Nirmatrelvir/Ritonavir in Patients at High Risk for Progression to Severe COVID-19 in the United States
    Carlson, Josh
    Foos, Volker
    Kasle, Adam
    Mugwagwa, Tendai
    Draica, Florin
    Wiemken, Timothy Lee
    Nguyen, Jennifer L.
    Cha-Silva, Ashley
    Migliaccio-Walle, Kristen
    Dzingina, Mendy
    VALUE IN HEALTH, 2024, 27 (02) : 164 - 172
  • [2] COST-EFFECTIVENESS OF NIRMATRELVIR/RITONAVIR IN COVID-19 PATIENTS AT HIGH-RISK FOR PROGRESSION IN SPAIN
    Peral, C.
    Azanza, J. R.
    Gonzalez del Castillo, J. M.
    Ferrando, R.
    Molero Garcia, J. M.
    Soriano, A.
    Ariznavarreta Martin, A.
    Gari, C.
    De Lossada Juste, A.
    Lopez Gomez, V
    VALUE IN HEALTH, 2024, 27 (12) : S129 - S129
  • [3] Cost-effectiveness of nirmatrelvir/ritonavir in COVID-19 patient groups at high risk for progression to severe COVID-19 in the Netherlands
    Duarte, Carlos H. Arteaga
    Peters, Michel L.
    de Goeij, Michelle H. M.
    Spijkerman, Roy
    Postma, Maarten J.
    COST EFFECTIVENESS AND RESOURCE ALLOCATION, 2025, 23 (01):
  • [4] Cost-Effectiveness of Nirmatrelvir/Ritonavir in COVID-19 Patients at High-Risk for Progression in Spain
    Azanza, Jose Ramon
    Gonzalez Del Castillo, Juan Maria
    Ferrando, Raul
    Molero, Jose Maria
    Soriano, Alex
    Peral, Carmen
    de Lossada, Alfonso
    Bellmunt, Alba
    Gari, Carla
    Mugwagwa, Tendai
    Lopez-Gomez, Vanessa
    JOURNAL OF MEDICAL VIROLOGY, 2025, 97 (03)
  • [5] Cost-effectiveness of nirmatrelvir/ritonavir for high-risk adult outpatients with COVID-19 in Japan
    Mizuno, Takahito
    Kondo, Yu
    Sakai, Mikiyasu
    Saneyasu, Kenichi
    Kojima, Ryota
    Miyake, Yoshio
    JOURNAL OF INFECTION AND CHEMOTHERAPY, 2024, 30 (08) : 716 - 724
  • [6] Effectiveness of Molnupiravir and Nirmatrelvir-Ritonavir in Hospitalized Patients With COVID-19
    Focosi, Daniele
    Nicastri, Emanuele
    ANNALS OF INTERNAL MEDICINE, 2023, 176 (10)
  • [7] Effectiveness of Molnupiravir and Nirmatrelvir-Ritonavir in CKD Patients With COVID-19
    Cheng, Franco Wing Tak
    Yan, Vincent Ka Chun
    Wan, Eric Yuk Fai
    Chui, Celine Sze Ling
    Lai, Francisco Tsz Tsun
    Wong, Carlos King Ho
    Li, Xue
    Zhang, Irene Ran
    Tang, Sydney Chi Wai
    Wong, Ian Chi Kei
    Chan, Esther Wai Yin
    KIDNEY INTERNATIONAL REPORTS, 2024, 9 (05): : 1244 - 1253
  • [8] Real-world Effectiveness of Molnupiravir and Nirmatrelvir/Ritonavir as Treatments for COVID-19 in Patients at High Risk
    Paraskevis, Dimitrios
    Gkova, Maria
    Mellou, Kassiani
    Gerolymatos, Gerasimos
    Psalida, Naya
    Gkolfinopoulou, Kassiani
    Kostaki, Evangelia-Georgia
    Loukides, Stylianos
    Kotanidou, Anastasia
    Skoutelis, Athanasios
    Thiraios, Eleftherios
    Saroglou, Georgios
    Zografopoulos, Dimitrios
    Filippou, Dimitrios
    Mossialos, Elias
    Zaoutis, Theoklis
    Gaga, Mina
    Tsiodras, Sotirios
    Antoniadou, Anastasia
    JOURNAL OF INFECTIOUS DISEASES, 2023, 228 (12): : 1667 - 1674
  • [9] Effectiveness of Molnupiravir and Nirmatrelvir-Ritonavir in Hospitalized Patients With COVID-19 Response
    Wan, Eric Yuk Fai
    Yan, Vincent Ka Chun
    Mok, Anna Hoi Ying
    Wong, Ian Chi Kei
    Chan, Esther Wai Yin
    ANNALS OF INTERNAL MEDICINE, 2023, 176 (10) : eL230265
  • [10] Nirmatrelvir/ritonavir or Molnupiravir for treatment of non-hospitalized patients with COVID-19 at risk of disease progression
    Butt, Adeel Ajwad
    Yan, Peng
    Shaikh, Obaid S.
    PLOS ONE, 2024, 19 (06):
12345